Diabetes Drug Might Also Help Some Patients Lose WeightPollakernst
By Steven Reinberg
TUESDAY, Aug. 18, 2015 (HealthDay News) — High doses of the diabetes drug liraglutide appear to assist patients with sort 2 diabetes lose weight, a unused study recommends.
In a trial financed by the drug’s maker Novo Nordisk, people who took 3 milligrams (mg) of liraglutide day by day over 56 weeks misplaced an average of 6 percent of their body weight (14 pounds).
According to Dr. Joel Zonszein, director of the Clinical Diabetes Center at Montefiore Medical Center in New York City, the U.S. Nourishment and Medicate Administration has affirmed a 3 mg-dose of liraglutide for the treatment of weight loss as it were. That higher dose is sold beneath the brand title Saxenda. A lower measurements of liraglutide (up to 1.8 mg a day) is endorsed for the treatment of sort 2 diabetes and is sold beneath the brand name Victoza.
“This is the primary study particularly designed to investigate the viability of liraglutide for weight management in patients with sort 2 diabetes at a measurements of 3 mg, and not shockingly was found to be compelling and endured for weight misfortune,” said Zonszein, who was not included within the trial.
“We require these considers, as clinicians have a enormous problem trying to use higher doses of liraglutide in corpulent patients who have diabetes. Ideally, the FDA will change the self-assertive confinements,” he included.
In the ponder, 846 overweight or stout patients with diabetes were haphazardly alloted to 1.8 mg or 3 mg of liraglutide or a placebo day by day. Those who took 1.8 mg lost an normal of near to 5 percent of their body weight (11 pounds), whereas patients taking a placebo misplaced an normal of 2 percent of their body weight (almost 5 pounds), the researchers detailed.
Concurring to the ponder, published Aug. 18 in the Diary of the American Therapeutic Association, 54 percent of those receiving the 3 mg-dose lost at slightest 5 percent of their body weight, compared with slightly more than 40 percent of those on the 1.8 mg dosage and fair over 21 percent of those taking a placebo.
Besides, fair over 25 percent of those on the high measurements of liraglutide lost at slightest 10 percent of their body weight, compared with 16 percent of those on the 1.8 mg-dose and close to 7 percent of those taking a fake treatment. Patients moreover taken after a reduced-calorie slim down and expanded their physical activity, the researchers noted.
“We now have prove that bolsters the use of the 3 mg-dose for weight loss in patients with sort 2 diabetes,” said lead researcher Dr. Melanie Davies, a professor of diabetes pharmaceutical at the University of Leicester in the U.K.
In individuals with diabetes, the 3 mg-dose of liraglutide made a difference patients accomplish clinically significant weight loss and more than 50 percent of patients were able to attain a weight loss of more than 5 percent, she said. “Too, this higher dosage of [liraglutide] given extra blood sugar-lowering than the measurements right now licensed to treat patients with diabetes,” she added.
Zonszein famous that since the higher measurements of liraglutide is not approved to treat diabetes, insurance companies will not cover the cost of the sedate when it is endorsed to diabetics.
“We will endorse up to 1.8 mg for diabetes, that’s the highest dose, but insurance companies will not endorse the 3 mg-dose for diabetes,” he said.
Liraglutide is expensive, Zonszein added, and the 3 mg-dose can cost $800 to $1,000 a month. Protections covers the cost as it were when that dosage is prescribed for weight misfortune.
Zonszein sees no problem using the higher dosage to control blood sugar as well as to assist patients lose weight. Liraglutide is portion of a drug regimen to control blood sugar that can incorporate metformin and other drugs, he clarified.
To get insurance companies to cover the higher measurements for a diabetic persistent, Zonszein said he must use a workaround. “When we call an protections company for endorsement, we do not tell them the patient is diabetic, but is obese,” he said.